Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

American Heart Journal

Volumn 162, Issue 4, 2011, Pages 597-605

  Ridker, Paul M ^a,b   Thuren, Tom ^c   Zalewski, Andrew ^c   Libby, Peter ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR;

ARTICLE; ATHEROTHOMBOSIS; ATHEROTHROMBOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FOLLOW UP; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; INFECTION; INFECTION COMPLICATION; INFLAMMATION; INJECTION SITE REACTION; INNATE IMMUNITY; LEUKOCYTE; LONG TERM CARE; MONOCYTE; MORTALITY; MUCKLE WELLS SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT INDICATION; VEIN THROMBOSIS;

ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; INTERLEUKIN-1BETA; MYOCARDIAL INFARCTION; RECURRENCE; STROKE; THROMBOSIS;

EID: 80053644777     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.06.012     Document Type: Article

References (64)

1. P. Libby, P.M. Ridker, and G.K. Hansson Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2009 2129 2138
2. G.K. Hansson, and P. Libby The immune response in atherosclerosis: a double-edged sword Nat Rev Immunol 6 2006 508 519 (Pubitemid 43980523)
3. P.M. Ridker C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2007 2129 2138 (Pubitemid 46783865)
4. P.M. Ridker, M. Cushman, and M.J. Stampfer Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 1997 973 979 (Pubitemid 27152782)
5. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843 (Pubitemid 30165206)
6. P.M. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565 (Pubitemid 35315836)
7. S. Kaptoge, E. Di Angelantonio, and G. Lowe C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 375 2010 132 140
8. N.R. Cook, J.E. Buring, and P.M. Ridker The effect of including C-reactive protein in cardiovascular risk prediction models for women Ann Intern Med 145 2006 21 29 (Pubitemid 46780601)
9. P.W. Wilson, M. Pencina, and P. Jacques C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study Circ Cardiovasc Qual Outcomes 1 2008 92 97
10. P.M. Ridker Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) J Thromb Haemost 7 Suppl 1 2009 332 339
11. P.M. Ridker, N. Rifai, and M.A. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 1998 839 844 (Pubitemid 28397432)
12. P.M. Ridker, N. Rifai, and M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965 (Pubitemid 32568149)
13. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
14. P.M. Ridker, J. MacFadyen, and P. Libby Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Am J Cardiol 106 2010 204 209
15. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28 (Pubitemid 40075677)
16. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288 (Pubitemid 44297094)
17. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38 (Pubitemid 40075678)
18. McMurray J.J., Kjekshus J., and Gullestad L. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
19. C.A. Dinarello The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1 N Engl J Med 343 2000 732 734
20. C.A. Dinarello Immunological and inflammatory functions of the interleukin-1 family Annu Rev Immunol 27 2009 519 550
21. J.E. Sims, and D.E. Smith The IL-1 family: regulators of immunity Nat Rev Immunol 10 2010 89 102
22. A. Stutz, D.T. Golenbock, and E. Latz Inflammasomes: too big to miss J Clin Invest 119 2009 3502 3511
23. Y. Ogura, F.S. Sutterwala, and R.A. Flavell The inflammasome: first line of the immune response to cell stress Cell 126 2006 659 662 (Pubitemid 44233635)
24. J.P. Drenth, and J.W. van der Meer The inflammasome-a linebacker of innate defense N Engl J Med 355 2006 730 732
25. F. Martinon, K. Burns, and J. Tschopp The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta Mol Cell 10 2002 417 426 (Pubitemid 35007355)
26. C.A. Dinarello, and S.M. Wolff The role of interleukin-1 in disease N Engl J Med 328 1993 106 113
27. W.P. Arend The balance between IL-1 and IL-1Ra in disease Cytokine Growth Factor Rev 13 2002 323 340
28. C.A. Dinarello Interleukin-1beta and the autoinflammatory diseases N Engl J Med 360 2009 2467 2470
29. W.F. Fearon, and D.T. Fearon Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist Circulation 117 2008 2577 2579
30. H.M. Hoffman, J.L. Mueller, and D.H. Broide Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome Nat Genet 29 2001 301 305 (Pubitemid 33096455)
31. H.J. Lachmann, I. Kone-Paut, and J.B. Kuemmerle-Deschner Use of canakinumab in the cryopyrin-associated periodic syndrome N Engl J Med 360 2009 2416 2425
32. I. Aksentijevich, S.L. Masters, and P.J. Ferguson An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist N Engl J Med 360 2009 2426 2437
33. S. Reddy, S. Jia, and R. Geoffrey An autoinflammatory disease due to homozygous deletion of the IL1RN locus N Engl J Med 360 2009 2438 2444
34. C.M. Larsen, M. Faulenbach, and A. Vaag Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 2007 1517 1526 (Pubitemid 46588416)
35. M.A. Lowes, A.M. Bowcock, and J.G. Krueger Pathogenesis and therapy of psoriasis Nature 445 2007 866 873
36. F. Martinon, V. Petrilli, and A. Mayor Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 2006 237 241 (Pubitemid 43372104)
37. V. Casini-Raggi, L. Kam, and Y.J. Chong Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation J Immunol 154 1995 2434 2440
38. C.A. Dinarello An update on human interleukin-1: from molecular biology to clinical relevance J Clin Immunol 5 1985 287 297 (Pubitemid 16257932)
39. M.P. Bevilacqua, J.S. Pober, and G.R. Majeau Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells J Exp Med 160 1984 618 623 (Pubitemid 14052522)
40. M.P. Bevilacqua, J.S. Pober, and M.E. Wheeler Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines J Clin Invest 76 1985 2003 2011 (Pubitemid 16196076)
41. P. Libby, J.M. Ordovas, and K.R. Auger Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells Am J Pathol 124 1986 179 185
42. P. Libby, J.M. Ordovas, and L.K. Birinyi Inducible interleukin-1 gene expression in human vascular smooth muscle cells J Clin Invest 78 1986 1432 1438 (Pubitemid 17219503)
43. P. Libby, S.J. Warner, and G.B. Friedman Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids J Clin Invest 81 1988 487 498 (Pubitemid 18075245)
44. R. Dewberry, H. Holden, and D. Crossman Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2394 2400
45. J. Chamberlain, D. Evans, and A. King Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice Am J Pathol 168 2006 1396 1403
46. H. Kirii, T. Niwa, and Y. Yamada Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice Arterioscler Thromb Vasc Biol 23 2003 656 660 (Pubitemid 36438080)
47. K. Isoda, M. Shiigai, and N. Ishigami Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury Circulation 108 2003 516 518 (Pubitemid 36961162)
48. K. Isoda, S. Sawada, and N. Ishigami Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 24 2004 1068 1073 (Pubitemid 38737833)
49. F. Merhi-Soussi, B.R. Kwak, and D. Magne Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice Cardiovasc Res 66 2005 583 593 (Pubitemid 40725770)
50. R. Elhage, A. Maret, and M.T. Pieraggi Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice Circulation 97 1998 242 244 (Pubitemid 28067308)
51. H. Chi, E. Messas, and R.A. Levine Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications Circulation 110 2004 1678 1685 (Pubitemid 39297993)
52. J. Chamberlain, J. Gunn, and S. Francis Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries Cardiovasc Res 44 1999 156 165 (Pubitemid 29431693)
53. H. Shimokawa, A. Ito, and Y. Fukumoto Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor J Clin Invest 97 1996 769 776 (Pubitemid 26057096)
54. A.C. Morton, N.D. Arnold, and J. Gunn Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model Cardiovasc Res 68 2005 493 501 (Pubitemid 41566569)
55. J. Galea, J. Armstrong, and P. Gadsdon Interleukin-1 beta in coronary arteries of patients with ischemic heart disease Arterioscler Thromb Vasc Biol 16 1996 1000 1006 (Pubitemid 26266899)
56. A. Kastrati, W. Koch, and P.B. Berger Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting J Am Coll Cardiol 36 2000 2168 2173
57. G. Patti, A. D'Ambrosio, and A. Dobrina Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease J Thromb Thrombolysis 14 2002 139 143 (Pubitemid 36559680)
58. S.E. Francis, N.J. Camp, and R.M. Dewberry Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease Circulation 99 1999 861 866 (Pubitemid 29094297)
59. P.S. Olofsson, Y. Sheikine, and K. Jatta A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development. The interleukin-1beta:interleukin-1 receptor antagonist balance in atherosclerosis Circ J 73 2009 1531 1536
60. I. Ikonomidis, J.P. Lekakis, and M. Nikolaou Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis Circulation 117 2008 2662 2669
61. D.C. Crossman, A.C. Morton, and J.P. Gunn Investigation of the effect of interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study) Trials 9 2008 8
62. P. Duewell, H. Kono, and K.J. Rayner NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 2010 1357 1361
63. K. Rajama, J. Lappalainen, and K. Oorni Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation PLoS ONE 5 2010 e11765
64. M.Y. Donath, and S.E. Schoelson Type 2 diabetes as an inflammatory disease Nat Rev Immunol 11 2011 98 107